Brokerages Set InflaRx N.V. (NASDAQ:IFRX) Price Target at $7.50

InflaRx N.V. (NASDAQ:IFRX) has earned a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $7.50.

A number of analysts have weighed in on IFRX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research report on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of InflaRx in a research note on Tuesday, December 30th. Guggenheim increased their price target on InflaRx from $10.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Leerink Partners reissued a “market perform” rating and issued a $2.00 price objective (down from $5.00) on shares of InflaRx in a research note on Wednesday, December 3rd. Finally, Wall Street Zen cut shares of InflaRx from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th.

Institutional Investors Weigh In On InflaRx

Hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE acquired a new position in InflaRx during the 3rd quarter worth approximately $3,316,000. Woodline Partners LP acquired a new stake in shares of InflaRx in the 1st quarter valued at approximately $766,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of InflaRx in the second quarter valued at approximately $262,000. T3 Companies LLC purchased a new stake in shares of InflaRx in the fourth quarter valued at approximately $294,000. Finally, Squarepoint Ops LLC grew its holdings in InflaRx by 29.1% during the third quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock worth $253,000 after acquiring an additional 42,489 shares during the period. Institutional investors and hedge funds own 42.39% of the company’s stock.

InflaRx Stock Performance

NASDAQ IFRX opened at $0.85 on Thursday. The firm’s fifty day moving average is $1.01 and its two-hundred day moving average is $1.16. InflaRx has a one year low of $0.71 and a one year high of $2.77. The firm has a market cap of $57.12 million, a PE ratio of -1.25 and a beta of 1.46.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.16). The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.03 million. Research analysts predict that InflaRx will post -1.04 earnings per share for the current year.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.